NCT07278362
Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Start date: Aug 31, 2026 to Nov 30, 2026
- Eligibility criteria shortened, about 25 words
- Secondary endpoints: details revised at 8 of 8 entries
- Site details revised at 2 of 2 sites
- Notable Start date: May 31, 2026 to Aug 31, 2026v3
- Notable Start date: Feb 2026 to May 31, 2026
- Primary completion date: Feb 2031 to May 31, 2031
- Study completion date: Feb 2032 to May 31, 2032
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Proportion of Participants with Disease Progression Within 12 Months After Initiating TRT
Timeframe: 12 months
Secondary (8)
Mean Change in Serum PSA Levels (ng/mL) from Baseline to 12 Months
Change in Total Testosterone Levels (ng/dL) from Baseline to 12 Months
Mean Change in Hematocrit Levels (%) from Baseline to 12 Months
Mean Change in Prostate Volume (mL) as measured by mpMRI from Baseline to 12 Months
Mean Change in EPIC-26 Scores from Baseline to 12 Months
Show 3 moreShow less
Mean Change in SF-12 Scores from Baseline to 12 Months
Mean Change in Aging Male's Symptoms Score (AMS) from Baseline to 12 Months
Progression-Free Survival (PFS) from Baseline to 5 Years
Arms and interventions
Testosterone cypionateExperimental
Participants will self-inject 100mg of testosterone cypionate once per week for 12 months
Drugs: Testosterone cypionate
Sites
2 sites in 1 country